Xiaoling Li, University of the Pacific, discusses how 3D-printed tablets combine multiple APIs and release profiles, scale out instead of up, and use layer-by-layer scanning.
|Articles|March 2, 2014
Forced Degradation Analysis for Ideal Packaging
Forced Degradation Analysis for Ideal Packaging
Advertisement
BilcareOptima™ is an advanced forced drug degradation analysis that determines a product’s susceptibility to various environmental factors, most prevalently humidity, temperature and light, to recommend the perfect packaging solution for products before they are ever packaged. In doing so, the service provides a level of insight into packaging-based product stability never before available in the United States.
Bilcare Reseach, Delaware City, DE
•
Advertisement
Related to this article
In October, FDA reorganized rare disease development around a fit-for-purpose framework and a new pathway for individualized gene editing. Regulators in Europe and the UK set out long-term plans for clinical trials, AI, and moving away from animal testing.
Clinical, manufacturing, safety, and commercial teams all lean on shared data. They need to agree on who publishes each data product, who can use it, and what evidence goes with it.
Structural modifications can improve peptide stability, solubility, and absorption to enable effective oral delivery.
The FDA approves VOCERYQ, the first DNA medicine, for RRP surgery reduction, raising plasmid, drug-device, and confirmatory trial manufacturing demands.
Continuous overall equipment effectiveness can be used to pinpoint hidden downtime and process bottlenecks in real time.
Subathra Ramamoorthy, Veranova, on how forced degradation and trace impurity profiling in potent APIs shape regulator-ready analytical methods.
The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
FDA’s New Inspection Playbook Counts Remote Assessments and MRA Reports Toward Facility Evaluations
2
Late-Phase Impurities Need Reference Standards: AAPS PharmSci 360 2026
3
RRP Accelerated Approval: What VOCERYQ Means for Manufacturing Teams
4
Who Answers for Your Data? Building a Life Sciences Data Mesh
5